Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Anal Bioanal Chem ; 398(7-8): 3051-61, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20957472

RESUMO

It has been shown that the HIV protease inhibitors indinavir and lopinavir may have activity against the human papilloma virus (HPV) type 16 inhibiting HPV E6-mediated proteasomal degradation of p53 in cultured cervical carcinoma cells. However, their mode and site of action is unknown. HPV-negative C33A cervical carcinoma cells and the same cells stably transfected with E6 (C33AE6) were exposed to indinavir and lopinavir at concentrations of 1 mM and 30 µM, respectively. The intracellular distribution of metabolites and metabolic changes induced by these treatments were investigated by Raman microspectroscopic imaging combined with the analysis of cell fractionation products by liquid chromatography-mass spectrometry (LC-MS). A uniform cellular distribution of proteins was found in drug-treated cells irrespective of cell type. Indinavir was observed to co-localise with nucleic acid in the nucleus, but only in E6 expressing cells. Principal components analysis (PCA) score maps generated on the full Raman hypercube and the corresponding PCA loadings plots revealed that the majority of metabolic variations influenced by the drug exposure within the cells were associated with changes in nucleic acids. Analysis of cell fractionation products by LC-MS confirmed that the level of indinavir in nuclear extracts was approximately eight-fold greater than in the cytoplasm. These data demonstrate that indinavir undergoes enhanced nuclear accumulation in E6-expressing cells, which suggests that this is the most likely site of action for this compound against HPV.


Assuntos
Inibidores da Protease de HIV/farmacologia , Papillomavirus Humano 16/isolamento & purificação , Infecções por Papillomavirus/tratamento farmacológico , Neoplasias do Colo do Útero/virologia , Fracionamento Celular , Linhagem Celular Tumoral , Cromatografia Líquida/métodos , Feminino , Humanos , Indinavir/farmacologia , Lopinavir , Proteínas Oncogênicas Virais/metabolismo , Infecções por Papillomavirus/metabolismo , Infecções por Papillomavirus/virologia , Análise de Componente Principal , Pirimidinonas/farmacologia , Proteínas Repressoras/metabolismo , Espectrometria de Massas por Ionização por Electrospray/métodos , Análise Espectral Raman/métodos , Transfecção , Proteína Supressora de Tumor p53/metabolismo , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/metabolismo
2.
BMC Vet Res ; 4: 30, 2008 Aug 08.
Artigo em Inglês | MEDLINE | ID: mdl-18691403

RESUMO

BACKGROUND: Ingestion of the poisonous weed ragwort (Senecio jacobea) by horses leads to irreversible liver damage. The principal toxins of ragwort are the pyrrolizidine alkaloids that are rapidly metabolised to highly reactive and cytotoxic pyrroles, which can escape into the circulation and bind to proteins. In this study a non-invasive in vitro model system has been developed to investigate whether pyrrole toxins induce specific modifications of equine blood proteins that are detectable by proteomic methods. RESULTS: One dimensional gel electrophoresis revealed a significant alteration in the equine plasma protein profile following pyrrole exposure and the formation of a high molecular weight protein aggregate. Using mass spectrometry and confirmation by western blotting the major components of this aggregate were identified as fibrinogen, serum albumin and transferrin. CONCLUSION: These findings demonstrate that pyrrolic metabolites can modify equine plasma proteins. The high molecular weight aggregate may result from extensive inter- and intra-molecular cross-linking of fibrinogen with the pyrrole. This model has the potential to form the basis of a novel proteomic strategy aimed at identifying surrogate protein biomarkers of ragwort exposure in horses and other livestock.


Assuntos
Proteínas Sanguíneas/metabolismo , Doenças dos Cavalos/diagnóstico , Doenças dos Cavalos/etiologia , Cavalos/metabolismo , Intoxicação por Plantas/veterinária , Senécio/intoxicação , Animais , Biomarcadores/metabolismo , Western Blotting , Fibrinogênio/metabolismo , Hemoglobinas/metabolismo , Cavalos/sangue , Intoxicação por Plantas/diagnóstico , Intoxicação por Plantas/etiologia , Plantas Tóxicas , Proteômica , Pirróis/intoxicação , Alcaloides de Pirrolizidina/intoxicação , Fatores de Tempo
3.
Mol Biosyst ; 10(3): 398-411, 2014 Mar 04.
Artigo em Inglês | MEDLINE | ID: mdl-24413339

RESUMO

Recently, it has been reported that anti-viral drugs, such as indinavir and lopinavir (originally targeted for HIV), also inhibit E6-mediated proteasomal degradation of mutant p53 in E6-transfected C33A cells. In order to understand more about the mode-of-action(s) of these drugs the metabolome of HPV16 E6 expressing cervical carcinoma cell lines was investigated using mass spectrometry (MS)-based metabolic profiling. The metabolite profiling of C33A parent and E6-transfected cells exposed to these two anti-viral drugs was performed by ultra performance liquid chromatography (UPLC)-MS and gas chromatography (GC)-time of flight (TOF)-MS. Using a combination of univariate and multivariate analyses, these metabolic profiles were investigated for analytical and biological reproducibility and to discover key metabolite differences elicited during anti-viral drug challenge. This approach revealed both distinct and common effects of these two drugs on the metabolome of two different cell lines. Finally, intracellular drug levels were quantified, which suggested in the case of lopinavir that increased activity of membrane transporters may contribute to the drug sensitivity of HPV infected cells.


Assuntos
Carcinoma/metabolismo , Inibidores da Protease de HIV/farmacologia , Metaboloma/efeitos dos fármacos , Metabolômica/métodos , Neoplasias do Colo do Útero/metabolismo , Carcinoma/virologia , Linhagem Celular Tumoral , Feminino , Expressão Gênica , Humanos , Proteínas Oncogênicas Virais/genética , Proteínas Repressoras/genética , Transfecção , Neoplasias do Colo do Útero/virologia
4.
Biomark Insights ; 2: 185-96, 2007 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-19662203

RESUMO

SUMMARY: The causes of many important diseases in animals are complex and multifactorial, which present unique challenges. Biomarkers indicate the presence or extent of a biological process, which is directly linked to the clinical manifestations and outcome of a particular disease. Identifying biomarkers or biomarker profiles will be an important step towards disease characterization and management of disease in animals. The emergence of post-genomic technologies has led to the development of strategies aimed at identifying specific and sensitive biomarkers from the thousands of molecules present in a tissue or biological fluid. This review will summarize the current developments in biomarker discovery and will focus on the role of transcriptomics, proteomics and metabolomics in biomarker discovery for animal health and disease.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa